Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cardiomix S R L is currently prosecuting patent applications in the Biotechnology & Pharmaceuticals technology area. The portfolio data reveals 1 pending office action. This matter is handled by 1 distinct examiner. The prosecution is also limited to 1 distinct art unit. This indicates a very focused legal landscape where the company's current filings are reviewed by a single official in a single technical department.
The busiest examiner for the company is OUSPENSKI, ILIA I, who holds 1 pending office action. This count is identical to the 1 total pending office action for the portfolio. Practitioners should focus their efforts on the specific preferences of OUSPENSKI, ILIA I. Because the number of distinct examiners is 1 and the number of distinct art units is 1, there is no diversity in the current review process. The 1 pending action represents the entire active workload, making the interaction with OUSPENSKI, ILIA I critical for the portfolio's success.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| OUSPENSKI, ILIA I | 1 | 77.3% | +20.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18387237 | AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS | OUSPENSKI, ILIA I | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18387237 | AUTOANTIBODIES AGAINST NaV1.5 CHANNEL AS BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME AND RELATED THERAPEUTIC METHODS | OUSPENSKI, ILIA I | 1644 | §112DP | Non-Final OA | — | Pending | Nov 06, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCardiomix S R L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ilia I Ouspenski has the most, with 1 of Cardiomix S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
